Total (n = 42) | Partially industry sponsored (n = 10) | Fully industry sponsored (n = 32) | |
---|---|---|---|
Roles and responsibilities of sponsor described | |||
Yes | 20 trials (48%) | 6 trials (60%) | 45 trials (44%) |
No | 22 trials (52%) | 4 trials (40%) | 18 trials (56%) |
Owner of data accumulated during the trial | |||
Sponsor | 20 trials (48%) | 1 trial (10%) | 19 trials (59%) |
Investigator | 6 trials (14%) | 6 trials (60%) | 0 trials (0%) |
Unclear | 16 trials (38%) | 3 trials (30%) | 13 trials (41%) |
Sponsor had the opportunity to review data during trial | |||
Yes | 8 trials (19%) | 0 trials (0%) | 8 trials (25%) |
No | 14 trials (33%) | 7 trials (70%) | 7 trials (22%) |
Unclear | 20 trials (48%) | 3 trials (30%) | 17 trials (53%) |
Sponsor had the opportunity to stop the trial early | |||
Yes, for any reason | 23 trials (55%) | 0 trials (0%) | 23 trials (72%) |
Yes, but only for specific reasons | 4 trials (9%) | 0 trials (0%) | 4 trials (13%) |
No | 7 trials (17%) | 6 trials (60%) | 1 trial (3%) |
Unclear | 8 trials (19%) | 4 trials (40%) | 4 trials (12%) |
Rights to publish were constricted | |||
Yes | 30 trials (71%) | 1 trial (10%) | 29 trials (91%) |
No | 7 trials (17%) | 7 trials (70%) | 0 trials (0%) |
Unclear | 5 trials (12%) | 2 trials (20%) | 3 trials (9%) |
Publication constraints mentioned in ICDs (n = 30) | |||
Yes | 0/30 trials (0%) | 0/1 trial (0%) | 0/29 trials (0%) |
No | 30/30 trials (100%) | 1/1 trial (100%) | 29/29 trials (100%) |